Speaker Profile

Ph.D., Chief Product Officer, Trapelo Health

Biography
Russell Ingersoll has 25 years of healthcare experience and proven success with the design and commercialization of information-based technology products for the clinical and life science industries. He has led product strategy and development at Trapelo Health since 2010. Under his leadership, the company developed clinical informatic tools and processes to build and maintain an evidence-based precision medicine knowledgebase. This knowledgebase now serves as the foundation of Trapelo, the first interoperable platform that enables real-time decision support, treatment selection and reimbursement assurance at the point of care. Prior to joining Trapelo Health, Russ served as VP of Product Development for MedTrust Online, an oncology-centric information portal; Senior Director of Business Development at Phylogeny, Inc., a functional genomics services company; co-Founder of Folio Biosciences, a biobank of clinically annotated specimens and co-founder of BioProtocol, an interactive laboratory protocol system for the research community.


Clinical Dx Showcase:
Trapelo Health

Trapelo Health is a health technology company on a mission to address the challenges that result from rapid changes in the science, technology and business of next-generation cancer care. Its product, Trapelo, is a win-win solution for doctors, labs and payers that need real-time, evidence-based information and full transparency to make patient-based decisions faster. As part of this commitment, Trapelo founded The Precision Medicine Podcast.

Precision Medicine and Laboratory Collaboration with NeoGenomics/ Trapelo Health
A partnership model that implements the use of the Trapelo Decision Support tool and Provides resources to internalize complementary lab methodologies.

 Session Abstract – PMWC 2022 Silicon Valley


The PMWC 2022 Data Applications in Clinical Diagnostics Showcase will provide a 15-minute time slot for selected organizations, including commercial companies, clinical testing labs, and medical research institutions, to present their latest advancements, insights, applications, and technologies to an audience of clinicians, leading investigators, academic institutions, pharma and biotech, investors, and potential clients. We will learn about new technologies and findings that promise expedited, cost-effective, and accurate clinical diagnosis for early disease detection, treatment decisions, and disease prevention.

- Clinical Dx/Oncology (including Liquid Biopsy)
- Clinical Dx/Cardio Vascular
- Clinical Dx/Nerodegenerative